150 likes | 327 Views
"Age Related Macular Degeneration - Pipeline Review, H2 2014"report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.
E N D
Category : Pharmaceuticals & Healthcare Age Related Macular Degeneration - Pipeline Review, H2 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/63082/age-related-macular-degeneration-pipeline-review
Summary Global Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H2 2014’, provides an overview of the Age Related Macular Degeneration’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Age Related Macular Degeneration Overview 11Therapeutics Development 12Pipeline Products for Age Related Macular Degeneration - Overview 12Pipeline Products for Age Related Macular Degeneration - Comparative Analysis 13Age Related Macular Degeneration - Therapeutics under Development by Companies 14Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 20Age Related Macular Degeneration - Pipeline Products Glance 22
Table of Content Clinical Stage Products 22Early Stage Products 23Unknown Stage Products 24Age Related Macular Degeneration - Products under Development by Companies 25Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 30Age Related Macular Degeneration - Companies Involved in Therapeutics Development 31Advanced Cell Technology, Inc. 31Alcon, Inc. 32Alkeus Pharmaceuticals, Inc. 33Allergan, Inc. 34AlphaMab Co., Ltd 35Amarna Therapeutics B.V. 36AngioGenex, Inc. 37Angstrom Pharmaceuticals, Inc. 38Aprogen, Inc. 39
List Of Tables Number of Products under Development for Age Related Macular Degeneration, H2 2014 18Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 21Number of Products under Development by Companies, H2 2014 (Contd..1) 22Number of Products under Development by Companies, H2 2014 (Contd..2) 23Number of Products under Development by Companies, H2 2014 (Contd..3) 24Number of Products under Development by Companies, H2 2014 (Contd..4) 25Number of Products under Investigation by Universities/Institutes, H2 2014 27Comparative Analysis by Clinical Stage Development, H2 2014 28Comparative Analysis by Early Stage Development, H2 2014 29
List Of Tables Comparative Analysis by Unknown Stage Development, H2 2014 30Products under Development by Companies, H2 2014 31Products under Development by Companies, H2 2014 (Contd..1) 32Products under Development by Companies, H2 2014 (Contd..2) 33Products under Development by Companies, H2 2014 (Contd..3) 34Products under Development by Companies, H2 2014 (Contd..4) 35Products under Investigation by Universities/Institutes, H2 2014 36Age Related Macular Degeneration - Pipeline by Advanced Cell Technology, Inc., H2 2014 37Age Related Macular Degeneration - Pipeline by Alcon, Inc., H2 2014 38Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2014 39Age Related Macular Degeneration - Pipeline by Allergan, Inc., H2 2014 40Age Related Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H2 2014 41
List of Figures Number of Products under Development for Age Related Macular Degeneration, H2 2014 18Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 20Number of Products under Investigation by Universities/Institutes, H2 2014 26Comparative Analysis by Clinical Stage Development, H2 2014 28Comparative Analysis by Early Stage Products, H2 2014 29Assessment by Monotherapy Products, H2 2014 90Number of Products by Top 10 Targets, H2 2014 91Number of Products by Stage and Top 10 Targets, H2 2014 91Number of Products by Top 10 Mechanism of Actions, H2 2014 94Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 94Number of Products by Top 10 Routes of Administration, H2 2014 96
Related Reports • Global Neurosurgery Market 2015-2019 • BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review • Ampio Pharmaceuticals, Inc. (AMPE) - Financial and Strategic SWOT Analysis Review • MiMedx Group, Inc (MDXG) - Financial and Strategic SWOT Analysis Review • Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review
Related Reports • MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review • Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review • RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review • Pharmaceuticals & Healthcare Market Research Reports
Age Related Macular Degeneration - Pipeline Review, H2 2014 Published: Oct 2014 | 252 Pages Age Related Macular Degeneration - Pipeline Review, H2 2014 report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Price
Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news